mGluR5 Silent Allosteric Modulator For Treatment of Alzheimer's Disease

• Background: mGluR5 has been identified as part of a cell-surface complex that binds to Ab oligomers, which leads to synaptic loss and neuronal death.
• A small molecule silent allostericmodulator (SAM) has been identified that blocks Ab binding, but does not interfere with normal glutamate signaling.
• Treatment of AD mice with SAM improves memory and learning (Fig.1), and ameliorates synaptic loss (Fig.2).
• IP status: Extensive patent portfolio covers novel composition of matter and is available for licensing.
• Lead Innovator: Stephen M. Strittmatter, M.D., Ph.D.